Alligator Bioscience And Aptevo Therapeutics Announce Interim Data Of Dose Escalation Phase Of ALG.APV-527 Phase 1 Study In Solid Tumor Cancers Expressing Tumor Antigen 5T4
Portfolio Pulse from Benzinga Newsdesk
Alligator Bioscience (ATORX) and Aptevo Therapeutics (NASDAQ:APVO) announced positive interim data from their Phase 1 trial of ALG.APV-527 for solid tumors expressing 5T4. The trial showed favorable drug exposure, confirmed biological activity, and early signs of clinical activity in heavily pretreated patients. The trial is over 50% enrolled, with dose escalation ongoing. Both companies highlighted the potential of ALG.APV-527 in treating multiple tumor types and expressed optimism for future development.
March 07, 2024 | 1:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aptevo Therapeutics announced positive interim results from the Phase 1 trial of ALG.APV-527, showing favorable drug exposure and signs of clinical activity in solid tumors.
The positive interim data from the Phase 1 trial of ALG.APV-527, a collaborative effort with Alligator Bioscience, indicates favorable drug exposure and biological activity. This news is likely to be viewed positively by investors, as it suggests potential for future development and commercial success, thus potentially leading to an increase in Aptevo's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Alligator Bioscience announced positive interim results from the Phase 1 trial of ALG.APV-527, showing favorable drug exposure and signs of clinical activity in solid tumors.
The positive interim data from the Phase 1 trial of ALG.APV-527, a collaborative effort with Aptevo Therapeutics, indicates favorable drug exposure and biological activity. This news is likely to be viewed positively by investors, as it suggests potential for future development and commercial success, thus potentially leading to an increase in Alligator Bioscience's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90